# Inhibrx Biosciences share price today (Inhibrx Biosciences, Inc., INBX)

> Inhibrx Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. INBX · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/inbx

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $80.28 (−0.5% in a year)
- Revenue (Jun 2025): $1.3 M (+1,200.0% on a year ago)
- Profit (Jun 2025), incl. one-off: −$28.7 M (one-off item, see below)
- ROE: −1,752%, FY25

The main question: the share price moved −0.5% in a year while yearly earnings per share moved −108.0%. The difference came from the market paying a higher multiple. ## What is the Inhibrx Biosciences share price today? Inhibrx Biosciences, Inc.'s share price was $80.28 at the close on 5 November 2026. That is 13.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $58 and $134, and at that close it sat 29% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 2 weeks running. Over the last 1 year the share price moved +269% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 23 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Inhibrx Biosciences pay? Inhibrx Biosciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Inhibrx Biosciences on? Inhibrx Biosciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Inhibrx Biosciences profitable? Inhibrx Biosciences, Inc. posted a net loss of $28.7 M in the Jun 2025 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $140 M. That loss is 2,204.2% of the quarter's revenue. The same quarter a year earlier lost $51.8 M. 11 of the last 12 reported quarters were loss-making. Jun 2025 profit was −$28.7 M, −101.5% on a year earlier. For the full year, FY25 profit was −$140 M (−108.3% on the year before). Read this profit with care: at −$28.7 M it is bigger than the quarter's whole revenue of $1.3 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −2,106.8% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Inhibrx Biosciences make, and is it growing? Inhibrx Biosciences, Inc. reported $1.3 M of revenue in the Jun 2025 quarter, +1,200.0% on the same quarter a year earlier. Over 4 years it has grown −34.9% a year on average. The last full year, FY25, came in at $1.3 M. FY25 revenue was $1.3 M, +550.0% on the year before. Recent pace: the last four quarters grew +446.5% on average, against −34.9% a year over the longer run, so this year is growing faster than its own long-run rate. ## How much of every $100 of sales does Inhibrx Biosciences keep? Inhibrx Biosciences, Inc.'s sales have fallen to very little: FY25 revenue was $1.3 M, against $7.2 M in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Inhibrx Biosciences' profit turning into cash? Inhibrx Biosciences, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $130 M of cash, against −$140 M of profit. After $31.0 K of spending on assets, free cash was −$130 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Inhibrx Biosciences' cash go? Inhibrx Biosciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $7.2 M on assets over the last 3 years. Averaged over those years that is 185.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $7.2 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Inhibrx Biosciences' P/E ratio, and how does it compare with its own history? Inhibrx Biosciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Inhibrx Biosciences, Inc. at 908.9× its FY25 revenue of $1.3 M. The P/E comes back here once profit turns positive. Why the multiple is where it is: over the past year earnings per share moved −108.0% while the price moved −0.5%. The price did better than earnings, which pushed the multiple up within its own range. ## Is the Inhibrx Biosciences business getting better or worse? Inhibrx Biosciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Inhibrx Biosciences earn on its capital? Inhibrx Biosciences, Inc. earned a ROE of −1,752% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −90%, a number that says nothing useful about the business. ## Does Inhibrx Biosciences have too much debt? Inhibrx Biosciences, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 1.35 in FY21 to 13.39 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Inhibrx Biosciences shareholding pattern? 39.8% of Inhibrx Biosciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 13.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Inhibrx Biosciences from balance-sheet trouble? For Inhibrx Biosciences, Inc., the Z-score is −1.92. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −1.92 is inside the danger zone, so the balance sheet is a real risk. ## How does Inhibrx Biosciences rank in its industry? There is no score against its industry: Inhibrx Biosciences, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Inhibrx Biosciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Inhibrx Biosciences in size? Inhibrx Biosciences is the 105th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Nektar Therapeutics, MannKind Corporation and Silence Therapeutics plc. Just below it: Verastem, Inc., Janux Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. ### Biotechnology companies close in size

1. [Nektar Therapeutics](https://www.sectoralpha.in/us/stocks/nktr) $1.2 billion
2. [MannKind Corporation](https://www.sectoralpha.in/us/stocks/mnkd) $1.2 billion
3. [Silence Therapeutics plc](https://www.sectoralpha.in/us/stocks/sln) $1.2 billion
4. Inhibrx Biosciences, Inc. $1.2 billion
5. [Verastem, Inc.](https://www.sectoralpha.in/us/stocks/vstm) $1.1 billion
6. [Janux Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/janx) $1.1 billion
7. [Rigel Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rigl) $958 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Red Violet, Inc.](https://www.sectoralpha.in/us/stocks/rdvt) $1.3 billion · Software - Application
2. [Two Harbors Investment Corp.](https://www.sectoralpha.in/us/stocks/two) $1.3 billion · REIT - Mortgage
3. Inhibrx Biosciences, Inc. $1.3 billion
4. [Alexander's, Inc.](https://www.sectoralpha.in/us/stocks/alx) $1.3 billion · REIT - Retail
5. [Forestar Group Inc.](https://www.sectoralpha.in/us/stocks/for) $1.3 billion · Real Estate - Development

## What else do people ask about Inhibrx Biosciences? ### What were Inhibrx Biosciences's latest quarterly results? Inhibrx Biosciences, Inc. reported revenue of $1.3 M and a net loss of $28.7 M for the Jun 2025 quarter. Revenue rose 1,200.0% and profit fell 101.5% compared with a year earlier. Earnings per share were −$1.85. The operating margin was −2,106.8%, 1,58,791.2 percentage points higher than a year earlier (as of 5 November 2026). ### What is Inhibrx Biosciences's market cap? Inhibrx Biosciences, Inc.'s market capitalisation is $1.2 B at a stock price of $80.28. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### Is Inhibrx Biosciences growing? Yes, Inhibrx Biosciences, Inc. is growing. In the latest quarter, revenue was +1,200.0% on a year earlier and profit −101.5%, and the margin moved +1,58,791.2 percentage points to −2,106.8%. Over the last four quarters, results have been improving (as of 5 November 2026). ### How is Inhibrx Biosciences performing? Inhibrx Biosciences, Inc.'s latest readings are below. In its latest quarter, revenue rose 1,200.0% and profit fell 101.5% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Inhibrx Biosciences's stock price go up? This page does not forecast Inhibrx Biosciences, Inc.'s stock price. What it shows instead: the stock price is $80.28. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### What could break the Inhibrx Biosciences story? The main question: the share price moved −0.5% in a year while yearly earnings per share moved −108.0%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Inhibrx Biosciences a stock worth studying right now? What the numbers show: Inhibrx Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.